Discover they major updates in oncology from the 2024 ESMO Congress, including featured breakthroughs from the leading ...

Olomorasib was put through its paces in combination with MSD’s PD-1 inhibitor Keytruda (pembrolizumab) in the phase 1/2 LOXO-RAS-20001 study, which included 17 previously untreated patients.

Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for the FDA's decision on its KRAS inhibitor adagrasib in non-small cell lung cancer (NSCLC).

After a median follow-up of 75 months, the 5-year OS was 86.6% in patients who received pembrolizumab (Keytruda) before and after surgery compared with 81.7% in those who received only neoadjuvant ...

The recent ESMO 2024 data highlighted significant advancements in immunotherapy. Check out the results from Merck, BMY, ...

BARCELONA, Spain — Adding pembrolizumab to standard concurrent chemoradiotherapy (CCRT) significantly improves overall survival in patients with high-risk, locally advanced cervical cancer ...

In patients with early-stage triple-negative breast cancer, the phase 3 KEYNOTE-522 trial showed significant improvements in pathological complete response and event-free survival with the ...

Source: Getty Images Updated data support the use of perioperative pembrolizumab as part of standard care for patients with high-risk, early TNBC, according to Peter Schmid, MD, PhD. At 5 years ...

In this audio interview, Editor-in-Chief Eric Rubin and NEJM Evidence Associate Editor Oladapo Yeku discuss research being presented at the 2024 European Society of Medical Oncology annual meeting.

NEW YORK – Bristol Myers Squibb's KRAS inhibitor Krazati (adagrasib) has been shown in a Phase III trial to be an effective treatment for patients with previously treated KRAS G12C-mutant non-small ...